CureVac N.V.
CureVac N.V. (CVAC) Revenue
Annual & quarterly revenue history · segment & region breakdown
CVAC · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCureVac N.V. trailing twelve-month (TTM) revenue is $0.07B, an increase of 895.54% year-over-year from $0.54B in FY2024.
Revenue trend
2024 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.54B | +$0.48B | +895.54% |
| 2023-12-31 | $0.05B | -$0.01B | -20.26% |
| 2022-12-31 | $0.07B | -$0.04B | -34.54% |
| 2021-12-31 | $0.10B | +$0.05B | +110.61% |
| 2020-12-31 | $0.05B | +$0.03B | +180.78% |
| 2019-12-31 | $0.02B | +$0.00B | +35.31% |
| 2018-12-31 | $0.01B | — | — |
Compare revenue vs peers
BiotechnologyCompare CVAC revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income CureVac N.V. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
CureVac N.V. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from CureVac N.V.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CVAC revenue · 4 questionsCVAC's trailing twelve-month (TTM) revenue is $0.07B. That is an increase of 895.54% year-over-year from $0.54B in FY2024.
▸ Source: FMP · CureVac N.V. SEC filings · GAAP · CureVac N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026